anika therapeut - ANIK

ANIK

Close Chg Chg %
20.88 -0.27 -1.29%

Open Market

20.61

-0.27 (1.29%)

Volume: 1.74K

Last Updated:

Sep 10, 2026, 10:34 AM EDT

Company Overview: anika therapeut - ANIK

ANIK Key Data

Open

$20.88

Day Range

20.61 - 20.88

52 Week Range

8.37 - 22.53

Market Cap

$281.58M

Shares Outstanding

13.38M

Public Float

12.54M

Beta

0.20

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.27

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

113.51K

 

ANIK Performance

1 Week
 
1.11%
 
1 Month
 
-1.77%
 
3 Months
 
42.93%
 
1 Year
 
142.68%
 
5 Years
 
-46.87%
 

ANIK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About anika therapeut - ANIK

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

ANIK At a Glance

Anika Therapeutics, Inc.
32 Wiggins Avenue
Bedford, Massachusetts 01730
Phone 1-781-457-9000 Revenue 112.82M
Industry Medical Specialties Net Income -10,880,000.00
Sector Health Technology Employees 235
Fiscal Year-end 12 / 2026
View SEC Filings

ANIK Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.221
Price to Book Ratio 0.93
Price to Cash Flow Ratio 12.32
Enterprise Value to EBITDA -20.023
Enterprise Value to Sales 0.945
Total Debt to Enterprise Value 0.246

ANIK Efficiency

Revenue/Employee 480,080.851
Income Per Employee -46,297.872
Receivables Turnover 4.762
Total Asset Turnover 0.54

ANIK Liquidity

Current Ratio 4.718
Quick Ratio 3.86
Cash Ratio 2.624

ANIK Profitability

Gross Margin 56.557
Operating Margin -9.795
Pretax Margin -8.249
Net Margin -9.644
Return on Assets -4.774
Return on Equity -6.71
Return on Total Capital -5.88
Return on Invested Capital -5.774

ANIK Capital Structure

Total Debt to Total Equity 18.296
Total Debt to Total Capital 15.466
Total Debt to Total Assets 12.966
Long-Term Debt to Equity 16.865
Long-Term Debt to Total Capital 14.257
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Anika Therapeut - ANIK

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
156.24M 166.66M 119.91M 112.82M
Sales Growth
+5.71% +6.67% -28.05% -5.91%
Cost of Goods Sold (COGS) incl D&A
62.66M 63.57M 43.91M 49.01M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
16.35M 14.23M 5.69M 5.73M
Depreciation
8.55M 6.43M 5.01M 5.37M
Amortization of Intangibles
7.80M 7.80M 678.00K 357.00K
COGS Growth
-3.38% +1.46% -30.93% +11.62%
Gross Income
93.58M 103.09M 76.00M 63.81M
Gross Income Growth
+12.82% +10.16% -26.28% -16.04%
Gross Profit Margin
+59.89% +61.85% +63.38% +56.56%
2022 2023 2024 2025 5-year trend
SG&A Expense
112.98M 115.54M 81.10M 74.86M
Research & Development
28.18M 32.69M 25.54M 25.77M
Other SG&A
84.79M 82.85M 55.55M 49.09M
SGA Growth
+12.05% +2.27% -29.81% -7.70%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 75.19M
-
EBIT after Unusual Expense
(19.40M) (87.64M) (5.10M) (11.05M)
Non Operating Income/Expense
654.00K 2.31M 2.34M 1.74M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(18.75M) (85.33M) (2.76M) (9.31M)
Pretax Income Growth
-872.39% -355.17% +96.76% -236.72%
Pretax Margin
-12.00% -51.20% -2.31% -8.25%
Income Tax
(3.89M) (2.66M) 6.06M 672.00K
Income Tax - Current - Domestic
1.29M 3.46M 5.41M 361.00K
Income Tax - Current - Foreign
96.00K 312.00K 421.00K 250.00K
Income Tax - Deferred - Domestic
- - (4.50M) (6.46M)
-
Income Tax - Deferred - Foreign
(774.00K) 29.00K 229.00K 61.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(14.86M) (82.67M) (8.83M) (9.98M)
Minority Interest Expense
- - - -
-
Net Income
(14.86M) (82.67M) (8.83M) (9.98M)
Net Income Growth
-459.43% -456.34% +89.32% -13.04%
Net Margin Growth
-9.51% -49.60% -7.36% -8.85%
Extraordinaries & Discontinued Operations
- - (47.56M) (901.00K)
-
Discontinued Operations
- - (47.56M) (901.00K)
-
Net Income After Extraordinaries
(14.86M) (82.67M) (56.39M) (10.88M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(14.86M) (82.67M) (56.38M) (10.88M)
EPS (Basic)
-1.0205 -5.6405 -3.8302 -0.7588
EPS (Basic) Growth
-455.45% -452.72% +32.09% +80.19%
Basic Shares Outstanding
14.56M 14.66M 14.72M 14.34M
EPS (Diluted)
-1.0205 -5.6405 -3.8302 -0.7588
EPS (Diluted) Growth
-461.24% -452.72% +32.09% +80.19%
Diluted Shares Outstanding
14.56M 14.66M 14.72M 14.34M
EBITDA
(3.05M) 1.78M 587.00K (5.32M)
EBITDA Growth
-60.99% +158.60% -67.11% -1,006.64%
EBITDA Margin
-1.95% +1.07% +0.49% -4.72%

Snapshot

Average Recommendation BUY Average Target Price 17.50
Number of Ratings 2 Current Quarters Estimate 0.235
FY Report Date 09 / 2026 Current Year's Estimate 0.53
Last Quarter’s Earnings 0.42 Median PE on CY Estimate N/A
Year Ago Earnings 0.11 Next Fiscal Year Estimate 0.735
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 2
Mean Estimate 0.24 0.14 0.53 0.74
High Estimates 0.42 0.19 1.05 0.95
Low Estimate 0.05 0.09 0.01 0.52
Coefficient of Variance 111.33 50.51 138.75 41.37

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Anika Therapeut in the News